Effects of the Serotonin 1A, 2A, 2C, 3A, and 3B and Serotonin Transporter Gene Polymorphisms on the Occurrence of Paroxetine Discontinuation Syndrome
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Paroxetine discontinuation symptoms can at times be severe enough to reduce the quality of life. However, it is currently not possible to predict the occurrence of discontinuation syndrome before the initiation or discontinuation of paroxetine treatment. In this study, we investigated the effects of genetic polymorphisms in the serotonin 1A, 2A, 2C, 3A, and 3B receptor, the serotonin transporter, and the cytochrome P450 2D6 (CYP2D6) genes on the occurrence of paroxetine discontinuation syndrome. A consecutive series of 56 Japanese patients who had a diagnosis of major depressive or anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were treated with paroxetine. Paroxetine discontinuation syndrome was found in 35.7% of the patients by direct interview. Patients who stopped taking paroxetine abruptly experienced paroxetine discontinuation syndrome significantly more often than patients who had a tapering off of the dosage of medication. Patients who had the -1019C allele experienced paroxetine discontinuation syndrome more frequently than patients who had the -1019G homozygote (nominal P = 0.0423) of the serotonin 1A receptor gene. However, this result did not remain significant after the Bonferroni correction for multiple comparisons. The findings suggest that the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome and that C(-1019)G polymorphism of the serotonin 1A…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study (n = 56) with paroxetine, participants who tapered their paroxetine over an average duration of 38.6 weeks (range 2 to 197 weeks), titrated to the individual, had a 6.1% incidence of withdrawal syndrome, compared with 78.2% for abrupt discontinuation (Murata 2010).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Murata 2010
In the citing paper
“In another study patients who withdrew from SSRIs over up to four months had 5.1 DESS events, compared with 11.7 for patients who abruptly discontinued 35 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [35]
In the citing paper
“The authors did not report information on the duration of the withdrawal syndromes, probably because symptoms were treated reintroducing fluoxetine [10,57,58] or administering other drugs [1,5] .”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [57]
In the citing paper
“Studies thus indicate that short-term tapering regimens result in a lower proportion of patients succeeding in discontinuing antidepressants compared with a longer tapering period.”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [14]
In the citing paper
“The incidence and severity of withdrawal symptoms may depend on how the antidepressant is tapered”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [14]
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · cited 1×
“Studies of SSRI discontinuation syndrome that used a double-blind, placebo-substitution design with 107 and 192 samples have been reported.(4,29) Our study includes 23 patients who abruptly stopped taking the medication on their own and 33 patients who were tapered off of the dosage of their medication.”
MethodPolymorphism in serotonin transporter gene associated with susceptibility to major depression
Ogilvie, A. D., Battersby, S., Fink, G., Harmar, A. J., Goodwin, G. M., Bubb, V. J., & Dale Smith, C. A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90079-3 · Cited by 531
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303 · cited 1×
“Coupland et al reported that after the discontinuation of clomipramine and SSRIs, the most common symptom was dizziness and that other frequent symptoms were paresthesia, lethargy, and nausea in patients with major depressive or anxiety disorder.(13) They suggested that these symptoms resemble the most unpleasant sens…”
BackgroundStudy of Compulsive Buying in Depressed Patients
Lejoyeux, M., Tassain, V., Solomon, J., & AdAs, J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0406 · Cited by 271
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Yuan, X., Yamada, K., Ishiyama-Shigemoto, S., Koyama, W., & Nonaka, K. (2000) · Diabetologia · doi:10.1007/s001250050056 · Cited by 219
Association of the C(–1019)G 5-HT1A functional promoter polymorphism with antidepressant response
Lemonde, S., Du, L., Bakish, D., Hrdina, P., & Albert, P. R. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004699 · Cited by 212
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207
Hong, C.-J., Chen, T.-J., Yu, Y. W.-Y., & Tsai, S.-J. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500340 · Cited by 189 · cited 2×
“AC122707.(17) The PCR products were digested with HpyCH4IV and then separated on 3% agarose gel.”
MethodGreen, B. (2003) · Current Medical Research and Opinion · doi:10.1185/030079902125001353 · Cited by 187 · cited 1×
“It has been widely and successfully used in the treatment of major depressive and anxiety disorders.(6) However, clinical studies have reported that the occurrence of discontinuation syndrome is extremely higher in patients treated with paroxetine (ranging 29%Y66%) in comparison with other SSRIs.”
ResultMichelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181 · cited 1×
“Studies of SSRI discontinuation syndrome that used a double-blind, placebo-substitution design with 107 and 192 samples have been reported.(4,29) Our study includes 23 patients who abruptly stopped taking the medication on their own and 33 patients who were tapered off of the dosage of their medication.”
MethodChouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
(1997) · PubMed · Cited by 149
Antidepressant discontinuation: a review of the literature.
Lejoyeux, M., & Adès, J. (1997) · PubMed · Cited by 148
Discontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140
Comorbid Schizophrenia and Substance Abuse
Green, A. I., & Brown, E. S. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0906e08 · Cited by 112
Eap, C. B., Bouchoux, G., Amey, M., Cochard, N., Savary, L., & Baumann, P. (1998) · Journal of Chromatographic Science · doi:10.1093/chromsci/36.7.365 · Cited by 111 · cited 2×
“The plasma level of paroxetine was determined using the gas chromatographyYmass spectrometry method described by Eap et al.(26)”
MethodNewer antidepressants and the discontinuation syndrome.
Haddad, P. M. (1997) · PubMed · Cited by 101
Clinical management of antidepressant discontinuation.
Rosenbaum, J. F., & Zajecka, J. (1997) · PubMed · Cited by 99
Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment
Judge, R., Parry, M. G., Quail, D., & Jacobson, J. G. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00002 · Cited by 87
Hindmarch, I., Kimber, S., & Cockle, S. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00001 · Cited by 84 · cited 2×
“This is in good agreement with reports by Judge et al,(3) van Geffen et al,(5) and Hindmarch et al.(30) However, it is currently not possible to predict the occurrence of SSRI discontinuation syndrome before stoppage of the medication.”
ResultOzaki, N., Rosenthal, N. E., Pesonen, U., Lappalainen, J., Feldman‐Naim, S., Schwartz, P. J., Turner, E. H., & Goldman, D. A. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00649-4 · Cited by 83
Bogetto, F., Bellino, S., Revello, R. B., & Patria, L. (2002) · CNS Drugs · doi:10.2165/00023210-200216040-00006 · Cited by 80 · cited 2×
“Our results indicate that the most frequent discontinuation symptom was dizziness, which is consistent with reports by Michelson et al(4) and Bogetto et al.(7) Based on our observation, the symptoms are fairly distressing and uncomfortable.”
ResultFava, G. A., Bernardi, M., Tomba, E., & Rafanelli, C. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007462 · Cited by 80
van Geffen, E. C. G., Hugtenburg, J. G., Heerdink, E. R., van Hulten, R. P., & Egberts, A. C. G. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0921-x · Cited by 72
Possible Biological Mechanisms of the Serotonin Reuptake Inhibitor Discontinuation Syndrome
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · The Journal of Clinical Psychiatry · Cited by 69
Kaiser, R., Tremblay, P.-B., Sezer, O., Possinger, K., Roots, I., & Brockm??ller, J. (2004) · Pharmacogenetics · doi:10.1097/00008571-200405000-00001 · Cited by 65
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · PubMed · Cited by 61
Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea
Tanaka, M., Kobayashi, D., Murakami, Y., Ozaki, N., Suzuki, T., Iwata, N., Haraguchi, K., Ieiri, I., Kinukawa, N., Hosoi, M., et al. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007985 · Cited by 61
Self-citationHimei, A., & Okamura, T. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00005 · Cited by 56
Takahashi, H. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00056-1 · Cited by 55
Suzuki, Y., Sawamura, K., & Someya, T. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500256 · Cited by 54
Physiologic mechanisms underlying the antidepressant discontinuation syndrome.
Blier, P., & Tremblay, P. (2006) · PubMed · Cited by 49
Ueda, M., Hirokane, G., Morita, S., Okawa, M., Watanabe, T., Akiyama, K., & Shimoda, K. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.007 · Cited by 44 · cited 2×
“The 56 patients were divided into 3 subgroups by the number of CYP2D6 functional alleles described by Ueda et al.(28) Twenty-three patients had 2 functional alleles (*1/*1, *1/*2, or *2/*2), 23 had one functional allele (*1/*5, *1/*10, *2/*5, or *2/*10), and 10 had no functional alleles (*5/*10 or *10/*10) of the CYP2…”
BackgroundThe effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus
Javid, F. A., & Naylor, R. J. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00955-3 · Cited by 34
Tint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13
Wilson, S. J., Bailey, J., & Nutt, D. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2111-4 · Cited by 9 · cited 1×
“It is of interest that this frequent symptom, dizziness, resembles the characteristic symptom of motion sickness, which can be inhibited in animals by serotonin 1A (5HT1A) receptor agonists,(14) and that dizziness or light-headedness is an adverse effect reported commonly with 5-HT1A receptor agonists.(15) Therefore,…”
Background
Cited by
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“The risk of antidepressant discontinuation may also be associated with the C(-1019)G polymorphism of the serotonin 1A receptor gene (Murata et al., 2010).”
BackgroundFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
“…2004; Tsai et al., 2010) or side effects (Rau et al., 2004; Shams et al., 2006; Suzuki et al., 2006), other authors found lack of association (Murphy Jr. et al., 2003; Grasmader et al., 2004; Serretti et al., 2009; Murata et al., 2010), both for therapeutic and side effects (Peters et al., 2008).”
Background
Metadata
- Authors
- Murata, Y., Kobayashi, D., Imuta, N., Haraguchi, K., Ieiri, I., Nishimura, R., Koyama, S., & Mine, K.
- Affiliations
- Fukuoka University (JP)
- Kyushu University (JP)
- Corresponding author
- Murata, Yusuke
- Koyama, Susumu
- Mine, Kazunori
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-02
- Volume
- 30
- Issue
- 1
- Pages
- 11-17
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2003054844
- Cited by
- 37
- References
- 40
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 6 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2015: 3 · 2014: 2 · 2013: 4
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- serotonin receptor gene, serotonin transporter gene, CYP2D6, genetic polymorphism, major depressive disorder, anxiety disorders, pharmacogenetics, Japanese patients
- MeSH terms
- Adult, Aged, Anxiety Disorders, Depressive Disorder, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Polymorphism, Genetic, Receptors, Serotonin, Risk Factors, Substance Withdrawal Syndrome, Paroxetine, Antidepressive Agents, Second-Generation, Cytochrome P-450 CYP2D6, Genetic Predisposition to Disease, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2A, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin, 5-HT3, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.